Study Overview: This study is testing a new medicine called STK-012 for people with solid tumors, which are lumps of cancer that don't have a liquid form. It is in phase 1, which means it is the first time the medicine is being tested in humans to check how safe it is and to find the right dose. The study will also see how well STK-012 works alone and when given with another cancer medicine called pembrolizumab.
Key Definitions: A multicenter, open-label study means it is being done at different places, and everyone knows what medicines are being taken. Dose escalation is a process to find the safest and best dose of the medicine by slowly increasing it.
- Participation Requirements: You must have a specific type of tumor that got worse after usual treatments.
- Study Details: You might need to give a new tissue sample for testing.
- Exclusions: You cannot join if you've had other cancer treatments recently.
How understandable was the trial content above?
Hard to understand
Easy to understand